As per the tie-up, the company will receive from Cassiopea the exclusive right to develop and commercialise WINLEVI in Japan, Australia, New Zealand, Brazil, Mexico and Russia, Sun Pharma said in a statement.
Copyright © 2024 | WordPress Theme by MH Themes